NCT05643430 - ULTRA LONG: BioFreedom Ultra | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 27, 2024

Primary Completion Date

March 8, 2026

Study Completion Date

August 31, 2026

Conditions

Coronary Artery DiseaseHigh Bleeding Risk Patients

Interventions

DEVICE

BioFreedom Ultra

The BioFreedom Ultra CoCr DCS is a combination product consisting of two key components: the cobalt chromium stent platform coated abluminally with the active ingredient BA9TM (polymer and carrier free) and the delivery system.

Trial Locations (9)

63050

Pôle Santé République, Clermont-Ferrand

91300

Cardiovascular Institute Paris Sud (ICPS) L'Hôpital Privé Jacques Cartier, Massy

06700

Arnault Institute Tzanck, Saint-Laurent-du-Var

B15 2TH

University Hospitals Birmingham (UHB), Birmingham

BB2 3HH

Royal Blackburn Hospital, Blackburn

HU3 2JZ

Hull University Teaching Hospitals (HUTH), Hull

Unknown

United Lincolnshire Hospitals (ULH), Lincoln

NP44 8YN

The Grange University Hospital, Newport, Newport

WN1 2NN

Royal Albert Edward Infirmary, Wigan

All Listed Sponsors

lead

Biosensors Europe SA

INDUSTRY